Jennifer Jarrett - 15 Aug 2022 Form 4 Insider Report for Radius Health, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 15 Aug 2022
Net transaction value: -$124,800
SEC form: 4
Accepted by SEC: 15 Aug 2022, 16:16:10 UTC
Prior SEC filing: 21 Jun 2022
Next SEC filing: 20 Sep 2022
Source filing: View source filing
Reporting owner signature: /s/ Kim Clarke, as attorney-in-fact

Key filing fact

Jennifer Jarrett filed Form 4 for Radius Health, Inc. on 15 Aug 2022.

Key facts

This page summarizes Jennifer Jarrett's Form 4 filing for Radius Health, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Aug 2022, 16:16.

Change

Previous filing in this sequence was filed on 21 Jun 2022.
Current net transaction value: -$124,800.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RDUS transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $124,800
Shares: -30,000
Change %: -100%
Price: $4.16
Shares after: 0
Date: 15 Aug 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,000
Exercise price: $5.84
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Jennifer Jarrett is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

Pursuant to the Merger Agreement, at the Effective Time, these options automatically vested and were cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (without interest) (A) an amount in cash (less applicable Tax withholdings) equal to the product of (x) the total number of Shares subject to such option immediately prior to the effective time multiplied by (y) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option, and (B) one CVR for each Share subject thereto.

SEC remarks

Capitalized terms used herein without definition have the meanings ascribed to them in the Agreement and Plan of Merger, dated as of June 23, 2022, by and among Ginger Acquisition, Inc., Ginger Merger Sub, Inc. and Radius Health, Inc. (the "Merger Agreement").